Mirati Therapeutics And Aadi Bioscience Partner To Evaluate The Combination Of Adagrasib With Nab-sirolimus In Patients With Advanced Non-Small Cell Lung Cancer And Other Solid Tumors With A KRAS[G12C] Mutation
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial stage biopharmaceutical company focused on developing and commercializing